New Clinical Data Confirms Shingrix Vaccine Provides Strong Protection for Over a Decade

New 2026 clinical data confirms the Shingrix vaccine provides over 10 years of protection against shingles and PHN for adults 50 and older. Learn more here.

By: AXL Media

Published: Feb 20, 2026, 3:21 AM EST

Source: Verywell Health

Decade-Long Efficacy for the Recombinant Zoster Vaccine

The latest clinical data regarding the Shingrix vaccine (recombinant zoster vaccine) provides significant reassurance for aging populations, confirming that the two-dose regimen offers robust protection for more than 10 years. Initial studies had already established high efficacy in the years immediately following vaccination, but the new longitudinal results demonstrate that the immune system remains primed against the varicella-zoster virus well into the second decade post-administration. For adults over 50, the vaccine remains approximately 89% effective at the 10-year mark, a remarkably high figure for senior-focused immunizations.

Preventing the Complications of Postherpetic Neuralgia

The primary goal of the shingles vaccine is not only to prevent the characteristic painful rash but also to mitigate the risk of Postherpetic Neuralgia (PHN). PHN is a chronic, often debilitating nerve pain that can persist for months or even years after the rash has cleared. The recent data underscores that Shingrix remains highly effective approximately 89% to 91% in preventing PHN specifically. This long-term durability is a critical factor for healthcare providers when discussing the value of the vaccine with patients who may be hesitant about the two-dose requirement.

TRANSFORMATIVE ANALYSIS: The Shift from Zostavax to Shingrix

The transition from the older live-virus vaccine (Zostavax) to the recombinant Shingrix has fundamentally changed the landscape of preventative elder care. While Zostavax’s efficacy was known to wane significantly after just five years, Shingrix’s use of a non-live antigen combined with an adjuvant system has proven to trigger a much more durable "immune memory." This technological leap means that the likelihood of needing a booster in the near term is low, though researchers continue to monitor cohorts to determine if a third dose will ever be necessary for those in their 80s or 90s.